Trials / Terminated
TerminatedNCT04854499
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 193 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magrolimab | Administered intravenously |
| DRUG | Pembrolizumab | Administered intravenously |
| DRUG | Docetaxel | Administered intravenously |
| DRUG | 5-FU | Administered intravenously |
| DRUG | Cisplatin | Administered intravenously |
| DRUG | Carboplatin | Administered intravenously |
| DRUG | Zimberelimab | Administered intravenously |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2024-10-02
- Completion
- 2024-10-02
- First posted
- 2021-04-22
- Last updated
- 2025-11-19
- Results posted
- 2025-11-19
Locations
88 sites across 11 countries: United States, Australia, Belgium, France, Germany, Hong Kong, Italy, Poland, Portugal, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04854499. Inclusion in this directory is not an endorsement.